← Back
Data updated: Jul 17, 2026
IC TARGETS
Pharma Pharmaceuticals
IC TARGETS is a pharmaceutical company with 1 FDA-approved products.
1997
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Jul 23, 2026 — Rivoceranib + camrelizumab
5d Jul 23, 2026 — Rivoceranib + camrelizumab
Aug 10, 2026 — Oveporexton (TAK-861)
IC TARGETS's Key Drugs
IC TARGETS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
IC TARGETS's Recent FDA Approvals
New NDA/BLA approvals for IC TARGETS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
IC TARGETS's Therapeutic Areas
Disease areas where IC TARGETS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
IC TARGETS Pipeline Snapshot
Active clinical trials for IC TARGETS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1997-11-26
- Latest
- 2002-07-08
- Applications
- 1